Diaceutics (LON:DXRX) Hits New 1-Year High - What's Next?

Key Points

• Diaceutics' shares hit a new 52-week high of GBX 180 on Thursday, trading 246,222 shares after a prior close of GBX 174.
• Shore Capital raised its target from GBX 180 to GBX 215 and assigned a "buy" rating; the stock has three Buy ratings and a consensus target of GBX 193.33.
• The company has a market cap of £152.33 million with strong liquidity (quick ratio 9.92, current ratio 3.96) but a negative PE (-100) and a debt-to-equity ratio of 3.05.

Diaceutics PLC (LON:DXRX - Get Free Report)'s share price hit a new 52-week high during trading on Thursday . The company traded as high as GBX 180 and last traded at GBX 180, with a volume of 246222 shares. The stock had previously closed at GBX 174.

Analyst Ratings Changes

Separately, Shore Capital Group boosted their target price on shares of Diaceutics from GBX 180 to GBX 215 and gave the stock a "buy" rating in a report on Thursday, January 15th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of GBX 193.33.

Diaceutics Price Performance

The firm has a market cap of £152.33 million, a PE ratio of -100.00 and a beta of 0.94. The company has a quick ratio of 9.92, a current ratio of 3.96 and a debt-to-equity ratio of 3.05. The stock has a 50 day moving average price of GBX 155.28 and a two-hundred day moving average price of GBX 153.75.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.